company background image
300239 logo

Baotou Dongbao Bio-TechLtd SZSE:300239 Stock Report

Last Price

CN¥5.46

Market Cap

CN¥3.2b

7D

-3.2%

1Y

7.9%

Updated

27 May, 2025

Data

Company Financials

Baotou Dongbao Bio-Tech Co.,Ltd

SZSE:300239 Stock Report

Market Cap: CN¥3.2b

300239 Stock Overview

Engages in the research and development, production, and sale of gelatin, collagen, and additional products in the People’s Republic of China and internationally. More details

300239 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends2/6

Risk Analysis

No risks detected for 300239 from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Baotou Dongbao Bio-Tech Co.,Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Baotou Dongbao Bio-TechLtd
Historical stock prices
Current Share PriceCN¥5.46
52 Week HighCN¥6.59
52 Week LowCN¥4.25
Beta0.17
1 Month Change6.43%
3 Month Change-2.85%
1 Year Change7.91%
3 Year Change-22.55%
5 Year Change22.97%
Change since IPO5.55%

Recent News & Updates

Recent updates

Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price Boost

Oct 08
Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price Boost

We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)

Oct 01
We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)

Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022

May 27
Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022

Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)

Feb 28
Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)

Shareholder Returns

300239CN ChemicalsCN Market
7D-3.2%-1.3%-0.9%
1Y7.9%0.4%8.8%

Return vs Industry: 300239 exceeded the CN Chemicals industry which returned 0.4% over the past year.

Return vs Market: 300239 matched the CN Market which returned 8.8% over the past year.

Price Volatility

Is 300239's price volatile compared to industry and market?
300239 volatility
300239 Average Weekly Movement6.5%
Chemicals Industry Average Movement6.5%
Market Average Movement6.9%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 300239 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 300239's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19601,385Fang Liuwww.dongbaoshengwu.com

Baotou Dongbao Bio-Tech Co.,Ltd engages in the research and development, production, and sale of gelatin, collagen, and additional products in the People’s Republic of China and internationally. It offers gelatin for jelly, confection, yogurt, plasma substitute, tablets, softgel, photographic paper, and hard capsules; plasma gelatin substitute, hollow capsule, double protein dietary fiber, cosmetics, and other products; agglomerated collagen peptide; hydrolyzed collagen power and granule; collagen peptide power and granule; hydrolyzed fish collagen; collagen jars; and fish collagen peptide powder, as well as food additive and pharmaceutical gelatin. The company also engages in research and development, production, and sale of bio-organic fertilizers, including industrial and feed grade calcium hydrogen phosphate; inorganic and organic microorganisms fertilizers; nitrogen fertilizers; calcium amino acid fertilizer; bone-derived biological calcium fertilizer; and biological and refined organic fertilizer.

Baotou Dongbao Bio-Tech Co.,Ltd Fundamentals Summary

How do Baotou Dongbao Bio-TechLtd's earnings and revenue compare to its market cap?
300239 fundamental statistics
Market capCN¥3.24b
Earnings (TTM)CN¥79.07m
Revenue (TTM)CN¥831.19m
41.0x
P/E Ratio
3.9x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300239 income statement (TTM)
RevenueCN¥831.19m
Cost of RevenueCN¥637.41m
Gross ProfitCN¥193.78m
Other ExpensesCN¥114.71m
EarningsCN¥79.07m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin23.31%
Net Profit Margin9.51%
Debt/Equity Ratio30.5%

How did 300239 perform over the long term?

See historical performance and comparison

Dividends

0.5%
Current Dividend Yield
19%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 02:10
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Baotou Dongbao Bio-Tech Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Jie YaoEverbright Securities Co. Ltd.